Intraoperative Blood Pressure Management and Dexamethasone in Lung Cancer Surgery
Impact of Intraoperative Blood Pressure Management and Dexamethasone on Patient's Outcomes After Lung Cancer Surgery: A 2 × 2 Factorial Randomized Controlled Trial
Peking University First Hospital
1,988 participants
Apr 7, 2020
INTERVENTIONAL
Conditions
Summary
Surgery is the front-line therapy for non-small cell lung cancer (NSCLC) but postoperative complications remains high and patients' long-term outcome is still challenging. In addition to surgery, anesthetic management particularly intraoperative blood pressure management and use of dexamethasone may affect patients' early and long-term outcomes after surgery for NSCLC. This study aims to investigate the impact of intraoperative blood pressure management and dexamethasone administration on early and long-term outcomes in patients undergoing surgery for lung cancer.
Eligibility
Inclusion Criteria3
- Aged \>50 years but \<90 years.
- Diagnosed as resectable primary non-small cell lung cancer (stage IA-IIIA) and scheduled for radical surgery with an expected duration of \>2 hours.
- Agree to participate in this study and sign the informed consent.
Exclusion Criteria8
- Clinical examinations suggest non-resectable lung cancer or patients scheduled for a biopsy surgery.
- Recurrent or metastatic lung cancer.
- History of cancer or complicated with cancer in other organs.
- Long-term exposure to glucocorticoids or other immunosuppressant(s) due to autoimmune disease or organ transplantation.
- Uncontrolled hypertension (systolic blood pressure \>180 mmHg or diastolic blood pressure \>110 mmHg); or requirement of vasopressors to maintain blood pressure.
- Persistent atrial fibrillation, or acute cardiovascular events (acute coronary syndrome, stroke, or congestive heart failure) within 3 months.
- Severe hepatic dysfunction (Child-Pugh C) or renal failure (requirement of renal replacement therapy).
- Any other circumstances considered unsuitable for study participation by attending physicians or investigators.
Interventions
Dexamethasone (10 mg/2 ml) is administered before anesthesia induction.
Blood pressure is maintained within ±10% from baseline.
Placebo (2 ml normal saline) is administered before anesthesia induction.
Blood pressure is maintained according to routine practice.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04209218